- Conditions
- Congenital Heart Disease (CHD)
- Interventions
- 2 mL SunButyrate-TG, Placebo, 4 mL SunButyrate-TG
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 1 Month to 3 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Vitreomacular Adhesion
- Interventions
- Ocriplasmin 125µg, Placebo
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 20
- States / cities
- Campbell, California • San Francisco, California • Santa Barbara, California + 17 more
- Conditions
- Degenerative Osteoarthritis
- Interventions
- TG-C, Placebo Control
- Biological
- Lead sponsor
- Kolon TissueGene, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Anaheim, California • Beverly Hills, California + 23 more
- Conditions
- Hypertriglyceridemia, Diabetic Neuropathy
- Interventions
- omega-3-ethyl esters, Placebo
- Drug
- Lead sponsor
- Eastern Virginia Medical School
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Degenerative Osteoarthritis
- Interventions
- TG-C, Placebo Control
- Biological
- Lead sponsor
- Kolon TissueGene, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
- Conditions
- Dermatitis, Atopic, Pruritus, Dermatitis Eczema
- Interventions
- ASN008 TG, Placebo TG
- Drug
- Lead sponsor
- Asana BioSciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
- Conditions
- Dyslipidaemias
- Interventions
- GW590735, fenofibrate
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 45
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more
- Conditions
- Vitreomacular Adhesion
- Interventions
- 125 µg Ocriplasmin, Placebo
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 35 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- TissueGene-C, Normal Saline
- Biological · Drug
- Lead sponsor
- Kolon TissueGene, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Pinellas Park, Florida • Baltimore, Maryland • Philadelphia, Pennsylvania + 2 more
- Conditions
- Hypertriglyceridemia
- Interventions
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
- Drug
- Lead sponsor
- Amarin Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 18
- States / cities
- Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
- Conditions
- Hypertriglyceridemia
- Interventions
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
- Drug
- Lead sponsor
- Amarin Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 80
- States / cities
- Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
- Conditions
- Symptomatic Vitreomacular Adhesion
- Interventions
- ocriplasmin, placebo
- Drug
- Lead sponsor
- ThromboGenics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas